SG10202000447YA - Promoters for enhancing expression in poxviruses - Google Patents
Promoters for enhancing expression in poxvirusesInfo
- Publication number
- SG10202000447YA SG10202000447YA SG10202000447YA SG10202000447YA SG10202000447YA SG 10202000447Y A SG10202000447Y A SG 10202000447YA SG 10202000447Y A SG10202000447Y A SG 10202000447YA SG 10202000447Y A SG10202000447Y A SG 10202000447YA SG 10202000447Y A SG10202000447Y A SG 10202000447YA
- Authority
- SG
- Singapore
- Prior art keywords
- poxviruses
- promoters
- enhancing expression
- enhancing
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199681P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202000447YA true SG10202000447YA (en) | 2020-03-30 |
Family
ID=57068152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202000447YA SG10202000447YA (en) | 2015-07-31 | 2016-07-28 | Promoters for enhancing expression in poxviruses |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11753652B2 (enExample) |
| EP (1) | EP3329016B1 (enExample) |
| JP (1) | JP6851364B2 (enExample) |
| KR (1) | KR102565284B1 (enExample) |
| CN (1) | CN107922981B (enExample) |
| AU (1) | AU2016303378B2 (enExample) |
| CA (1) | CA2990549A1 (enExample) |
| DK (1) | DK3329016T3 (enExample) |
| ES (1) | ES2901468T3 (enExample) |
| IL (1) | IL256869B (enExample) |
| MX (1) | MX389312B (enExample) |
| RU (1) | RU2753884C2 (enExample) |
| SG (1) | SG10202000447YA (enExample) |
| WO (1) | WO2017021776A1 (enExample) |
| ZA (1) | ZA201800104B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7202362B2 (ja) | 2017-08-24 | 2023-01-11 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| EP3860641A1 (en) | 2018-10-05 | 2021-08-11 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| BR112021009856A8 (pt) | 2018-11-20 | 2021-09-08 | Bavarian Nordic As | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l |
| BR112022009798A2 (pt) | 2019-11-20 | 2022-10-18 | Bavarian Nordic As | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer |
| WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| CA3240596A1 (en) | 2021-12-23 | 2023-06-29 | Cigdem ATAY LANGBEIN | Therapy for modulating immune response with recombinant mva encoding il-12 |
| AU2024208643A1 (en) | 2023-01-12 | 2025-06-26 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| DE69133333T2 (de) * | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| RU2180352C2 (ru) | 1999-11-24 | 2002-03-10 | Государственный научный центр вирусологии и биотехнологии "Вектор" | ФРАГМЕНТ ГЕНОМА ВИРУСА ОСПЫ КУР ШТАММА "К", СОДЕРЖАЩИЙ ГЕН ТИМИДИНКИНАЗЫ, РЕКОМБИНАНТНЫЕ ПЛАЗМИДНЫЕ ДНК pTK1FPV И pTK2FPV, СОДЕРЖАЩИЕ ЭТУ ПОСЛЕДОВАТЕЛЬНОСТЬ, И РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pINTFPV1, ОБЛАДАЮЩАЯ СПОСОБНОСТЬЮ ИНТЕГРИРОВАТЬСЯ В ГЕНОМ ВИРУСА ОСПЫ КУР |
| WO2005048957A2 (en) | 2003-02-20 | 2005-06-02 | Therion Biologics Corporation | Novel insertion sites in pox vectors |
| EP1673458A4 (en) | 2003-10-15 | 2007-12-12 | Virax Dev Pty Ltd | FOR RETROVIRUS (e.g., HIV) AND CYTOKIN-CODING POXVIRUS VECTOR |
| DK2918598T3 (en) * | 2007-02-28 | 2019-04-29 | The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services | Brachyury polypeptides and methods of use |
| CN101775410B (zh) * | 2009-01-09 | 2011-11-16 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种鸡痘病毒载体穿梭质粒及其应用 |
| EP2419126B1 (en) * | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| CN102321637A (zh) * | 2011-09-09 | 2012-01-18 | 中国人民解放军军事医学科学院军事兽医研究所 | 中国鸡痘病毒282e4弱毒株全基因组序列及其应用 |
| WO2014043535A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
-
2016
- 2016-07-28 KR KR1020187000086A patent/KR102565284B1/ko active Active
- 2016-07-28 MX MX2018001055A patent/MX389312B/es unknown
- 2016-07-28 ES ES16775852T patent/ES2901468T3/es active Active
- 2016-07-28 RU RU2018106643A patent/RU2753884C2/ru active
- 2016-07-28 JP JP2018500943A patent/JP6851364B2/ja active Active
- 2016-07-28 WO PCT/IB2016/001183 patent/WO2017021776A1/en not_active Ceased
- 2016-07-28 US US15/747,844 patent/US11753652B2/en active Active
- 2016-07-28 SG SG10202000447YA patent/SG10202000447YA/en unknown
- 2016-07-28 DK DK16775852.3T patent/DK3329016T3/da active
- 2016-07-28 IL IL256869A patent/IL256869B/en unknown
- 2016-07-28 CN CN201680042251.3A patent/CN107922981B/zh active Active
- 2016-07-28 AU AU2016303378A patent/AU2016303378B2/en active Active
- 2016-07-28 EP EP16775852.3A patent/EP3329016B1/en active Active
- 2016-07-28 CA CA2990549A patent/CA2990549A1/en active Pending
-
2018
- 2018-01-05 ZA ZA2018/00104A patent/ZA201800104B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001055A (es) | 2018-05-17 |
| RU2753884C2 (ru) | 2021-08-24 |
| WO2017021776A1 (en) | 2017-02-09 |
| BR112018002172A2 (pt) | 2018-09-18 |
| KR20180033498A (ko) | 2018-04-03 |
| AU2016303378A1 (en) | 2018-01-25 |
| HK1254405A1 (en) | 2019-07-19 |
| EP3329016B1 (en) | 2021-10-20 |
| CN107922981B (zh) | 2022-02-25 |
| ZA201800104B (en) | 2022-04-28 |
| JP6851364B2 (ja) | 2021-03-31 |
| EP3329016A1 (en) | 2018-06-06 |
| RU2018106643A3 (enExample) | 2020-01-30 |
| CA2990549A1 (en) | 2017-02-09 |
| IL256869B (en) | 2022-07-01 |
| NZ738713A (en) | 2024-11-29 |
| AU2016303378B2 (en) | 2021-12-23 |
| KR102565284B1 (ko) | 2023-08-08 |
| RU2018106643A (ru) | 2019-08-28 |
| ES2901468T3 (es) | 2022-03-22 |
| DK3329016T3 (da) | 2022-01-10 |
| IL256869A (en) | 2018-03-29 |
| BR112018002172A8 (pt) | 2024-02-15 |
| US11753652B2 (en) | 2023-09-12 |
| CN107922981A (zh) | 2018-04-17 |
| JP2018521651A (ja) | 2018-08-09 |
| US20180216134A1 (en) | 2018-08-02 |
| MX389312B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201705846B (en) | Dual sized razor | |
| GB2524269B (en) | Virtual reality | |
| SG11201608388TA (en) | Applicator | |
| GB201512688D0 (en) | Aerofoil | |
| ZA201800104B (en) | Promoters for enhancing expression in poxviruses | |
| GB201418349D0 (en) | Virtual component alignment | |
| GB201412991D0 (en) | Applicator machine | |
| HUE072083T2 (hu) | Új promóterek | |
| GB201508845D0 (en) | Risk stratification | |
| GB201519120D0 (en) | Microprocessor interfaces | |
| IL256495A (en) | Algal promoters | |
| GB201523035D0 (en) | In terferometry | |
| GB201503105D0 (en) | Blisk | |
| GB201800737D0 (en) | Improvements in packaging | |
| GB2515404B8 (en) | Clipboard | |
| HUE037206T2 (hu) | Autokláv | |
| GB201519665D0 (en) | Interface | |
| GB201502617D0 (en) | Supports | |
| GB201408735D0 (en) | Application coordination | |
| GB201502544D0 (en) | Independent means | |
| GB201507702D0 (en) | Job swipe | |
| GB201509681D0 (en) | Risk stratification | |
| GB201508844D0 (en) | Risk stratification | |
| AU365778S (en) | Applicator | |
| AU365005S (en) | Top |